acalabrutinib
Selected indexed studies
- Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia. (N Engl J Med, 2025) [PMID:39976417]
- Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. (J Clin Oncol, 2021) [PMID:34310172]
- Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma. (J Clin Oncol, 2025) [PMID:40311141]
_Worker-drafted node — pending editorial review._
Connections
acalabrutinib is a side effect of
Sources
- Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia. (2025) pubmed
- Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. (2021) pubmed
- Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma. (2025) pubmed
- Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN. (2025) pubmed
- Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. (2020) pubmed
- Acalabrutinib. (2012) pubmed
- Acalabrutinib. (2006) pubmed
- Acalabrutinib for mantle cell lymphoma. (2019) pubmed
- Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. (2018) pubmed
- Acalabrutinib Versus Investigator's Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results. (2022) pubmed